Alecensa (alectinib capsules – Genentech) — Cigna
Non-Small Cell Lung Cancer – Adjuvant Therapy
Initial criteria
- Patient age ≥ 18 years
- Patient has anaplastic lymphoma kinase (ALK)-positive disease
- Medication is used following tumor resection (tumors ≥ 4 cm or node positive)
- The mutation was detected by an approved test
Approval duration
2 years total